FDA Approves Bristol Myers Squibb Anemia Treatment
Bristol Myers Squibb’s Reblozyl (luspatercept-aamt) is approved as a first-line treatment for anemia in adults with lower-risk myelodysplastic syndromes.
Bristol Myers Squibb announced FDA approval of Reblozyl (luspatercept-aamt) as a first-line treatment for anemia without previous erythropoiesis stimulating agent use (ESA-naïve) on Aug. 28, 2023. The drug is indicated for adult patients with low-to-intermediate-risk myelodysplastic syndromes (MDS) who may require regular red blood cell (RBC) transfusions.
According to a company press release, FDA approval was based on interim results from the Phase III COMMANDS trial. In the trial, 58.6% of patients treated with luspatercept-aamt achieved the primary endpoints of concurrent RBC transfusion independence of at least 12 weeks and mean hemoglobin increase of at least 1.5 grams per deciliter within the first 24 weeks. This was deemed to be superior efficacy to epoetin alfa, an ESA which had a 31.2% efficacy rate, regardless of ring sideroblast status.
“Today's expanded approval of [luspatercept-aamt] marks an important milestone in our commitment to MDS patients with anemia by providing a durable and more effective treatment option, with more convenient and less frequent administration,” said Wendy Short-Bartie, senior vice-president and general manager, U.S. Hematology and Cell Therapy, Bristol Myers Squibb, in the release. “We remain dedicated to addressing hard-to-treat diseases with significant burden to patients and look forward to bringing this important option earlier in the treatment process.”
“The majority of patients with MDS experience chronic anemia and require RBC transfusions,” said Tracey Iraca, executive director, MDS Foundation, in the release. “The approval of [luspatercept-aamt] in the first-line treatment of anemia for patients with lower-risk MDS represents a crucial step in making transfusion independence possible for more patients.”
Source: Bristol Myers Squibb
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
